LifePoint Health, Inc. (LPNT) Given a $69.00 Price Target by Robert W. Baird Analysts
LifePoint Health, Inc. (NASDAQ:LPNT) has been assigned a $69.00 target price by Robert W. Baird in a research report issued to clients and investors on Thursday. The firm presently has a “buy” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 26.14% from the stock’s previous close.
LPNT has been the topic of a number of other research reports. Zacks Investment Research raised LifePoint Health from a “sell” rating to a “hold” rating in a research report on Monday, August 21st. TheStreet lowered LifePoint Health from a “b-” rating to a “c+” rating in a research report on Wednesday, August 16th. BidaskClub raised LifePoint Health from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. ValuEngine lowered LifePoint Health from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $66.00 price target on shares of LifePoint Health in a research report on Wednesday, October 4th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company. LifePoint Health currently has a consensus rating of “Hold” and a consensus price target of $66.33.
LifePoint Health (NASDAQ LPNT) traded up 0.37% during trading on Thursday, reaching $54.70. The company’s stock had a trading volume of 359,548 shares. The firm has a market cap of $2.19 billion, a P/E ratio of 12.25 and a beta of 0.84. LifePoint Health has a 52 week low of $50.60 and a 52 week high of $70.95. The stock’s 50 day moving average is $56.62 and its 200-day moving average is $61.14.
LifePoint Health (NASDAQ:LPNT) last released its quarterly earnings results on Tuesday, August 1st. The company reported $0.96 EPS for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.06. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.64 billion. LifePoint Health had a return on equity of 7.40% and a net margin of 2.61%. LifePoint Health’s revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.69 earnings per share. On average, equities research analysts forecast that LifePoint Health will post $4.06 earnings per share for the current fiscal year.
WARNING: “LifePoint Health, Inc. (LPNT) Given a $69.00 Price Target by Robert W. Baird Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/12/lifepoint-health-inc-lpnt-given-a-69-00-price-target-by-robert-w-baird-analysts.html.
In other LifePoint Health news, Chairman William F. Carpenter III sold 17,653 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $65.06, for a total value of $1,148,504.18. Following the completion of the transaction, the chairman now directly owns 439,841 shares in the company, valued at $28,616,055.46. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.76% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of LPNT. Wells Fargo & Company MN grew its stake in LifePoint Health by 22.6% in the first quarter. Wells Fargo & Company MN now owns 21,951 shares of the company’s stock valued at $1,438,000 after purchasing an additional 4,045 shares in the last quarter. US Bancorp DE boosted its stake in shares of LifePoint Health by 1.6% during the 1st quarter. US Bancorp DE now owns 1,931 shares of the company’s stock worth $127,000 after acquiring an additional 30 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of LifePoint Health by 679.9% during the 1st quarter. UBS Asset Management Americas Inc. now owns 247,499 shares of the company’s stock worth $16,211,000 after acquiring an additional 215,763 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of LifePoint Health by 5.0% during the 1st quarter. Ameriprise Financial Inc. now owns 111,985 shares of the company’s stock worth $7,335,000 after acquiring an additional 5,287 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of LifePoint Health by 26.2% during the 1st quarter. JPMorgan Chase & Co. now owns 101,629 shares of the company’s stock worth $6,656,000 after acquiring an additional 21,083 shares during the period. Hedge funds and other institutional investors own 99.53% of the company’s stock.
LifePoint Health Company Profile
LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers and post-acute facilities. As of December 31, 2016, the Company operated 72 hospital campuses in 22 states, having a total of 9,424 licensed beds. It offers a range of general and specialized healthcare services to patients through a network of hospitals and outpatient facilities.
Receive News & Ratings for LifePoint Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.